Novavax

Our science has been featured in several new publications. Learn more about our research: https://lnkd.in/gUqYnxmx #MedicalProfessionals #ScientificCommunity

Novavax’s corporate growth strategy includes efforts to pursue additional partnerships for its late-stage and early-stage Research and Development assets and Matrix-M™ adjuvant alone. This growth strategy should position the Company for ongoing value creation, as additional partnerships are secured under a similar contractual framework, and broaden global access to our vaccine technology and the protections it can provide. Read the press release at: https://novav.ax/3OVLaJM

Novavax advances its corporate growth strategy through Sanofi partnership with achievement of first $50 million milestone. Read the press release at: https://novav.ax/4gyZOCI

#NEWS: Novavax today announced it has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Read the press release at: https://novav.ax/4iCikMm

#NEWS: Novavax initiates its COVID-19-Influenza Combination and stand-alone influenza Phase 3 trial. Read the press release at: https://novav.ax/3VyuvQl

#NEWS: Novavax sells its manufacturing facility in the Czech Republic to Novo Nordisk for $200 million. Read the press release at: https://novav.ax/4eZdeqf

We're excited to announce that we've partnered with Novavax, Inc. as our local COVID-19 vaccine partner. Located in Gaithersburg, Md., Novavax is committed to helping protect people from COVID infection with a vaccine platform that's built different. For more information, visit novavax.com

Novavax is here to make a difference. Today, we're thankful for all of the hard-working and innovative members of the Novavax team who make our science possible. Happy Thanksgiving! Learn more about Novavax here: https://www.novavax.com/

Targeting JN.1, the current "tree trunk," potentially increases the breadth of crossprotection against emerging strains in light of the possibility that future dominant JN.1-descendant strains may not be descendants of KP subvariants. Learn more here: https://lnkd.in/e8i3MgYT

The virus that causes COVID-19 has continuously mutated, evolving from the Wuhan strain in 2020 to new strains that have included the Alpha, Beta, Gamma, Delta, Omicron variants and XBB subvariants. As of early fall 2024, the primary subvariants circulating in the U.S. are descendants of the JN.1 strain. Learn about the value of targeting the JN.1 strain: https://lnkd.in/e8i3MgYT